Boston University School of Law
The Health Impact Fund (Hollis & Pogge 2008) is an innovative financing mechanism for global drug discovery and dissemination, separating the reward for successful R&D from the market price of the drug, also known as de-linkage. Aaron Kesselheim and Kevin Outterson have recently proposed a mechanism to reimburse companies for antibiotics according to their social value, but conditioned on achieving conservation goals to limit resistance (Kesselheim & Outterson 2010, 2011). This paper will explore whether this antibiotic resistance conservation proposal can be adapted to the framework of the Health Impact Fund. If these proposals can be meshed, then antibiotics might be an interesting therapeutic class for a test of the Health Impact Fund.
Kevin Outterson, Thomas Pogge & Aidan Hollis,
Combating Antibiotic Resistance Through the Health Impact Fund
Boston University School of Law, Law and Economics Research Paper
Available at: https://scholarship.law.bu.edu/faculty_scholarship/390
Published as: "Combating Antibiotic Resistance Through the Health Impact Fund," in The Globalization of Health Care: Legal and Ethical Issues 318, Glenn I. Cohen, ed., Oxford University Press (2013).